In clinical practice, the safety and efficacy of drug and nutritional/herbal supplementation used during pregnancy are primarily based upon empiric dosing regimens, anecdotal efficacy data, clinical experience, and limited case reports. The objective of this research is to determine the fetal drug exposure based on concentration of each drug/supplement evaluated that crosses the placental/trophoblastic barrier (PTB) and its possible effects on the fetus development
Current Status
Completed studies: Carboplatin, granisetron, docetaxel and cisplatin
Ongoing studies: paclitaxel, indomethacin
Future studies will focus on nausea medications and nutritional supplements
Long-term Goal
Increase the evidence for the safety use of medication and supplement use during pregnancy and breastfeeding.